LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 181

Search options

  1. Book ; Online ; E-Book: Lung cancer

    Gillaspie, Erin Alexis / Horn, Leora / Cass, Amanda S.

    an evidence-based approach to multidisciplinary management

    2023  

    Abstract: Care of the lung cancer patient--screening, diagnosis, and treatment--has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management covers every aspect of ... ...

    Author's details [edited by] Erin Alexis Gillaspie, Amanda S. Cass, Leora Horn
    Abstract "Care of the lung cancer patient--screening, diagnosis, and treatment--has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management covers every aspect of this fast-changing field, including new screening guidelines, new practice standards, and new treatment advances that have led to higher survival rates. This practical, clinically oriented resource provides thorough, evidence-based coverage from experts in the field, including the increasingly important precision medicine approach in lung cancer planning and management"--
    MeSH term(s) Lung Neoplasms.
    Keywords Lungs/Cancer
    Subject code 616.99/424
    Language English
    Dates of publication 2023-2024
    Size 1 online resource (xiv, 324 pages) :, illustrations (chiefly color)
    Publisher Elsevier Inc
    Publishing place Philadelphia, PA
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 0-323-69574-4 ; 9780323695732 ; 978-0-323-69574-9 ; 0323695736
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: COVID-19 in patients with cancer: managing a pandemic within a pandemic.

    Horn, Leora / Garassino, Marina

    Nature reviews. Clinical oncology

    2020  Volume 18, Issue 1, Page(s) 1–2

    MeSH term(s) COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19/virology ; Humans ; Medical Oncology/methods ; Neoplasms/chemically induced ; Neoplasms/epidemiology ; Neoplasms/therapy ; Pandemics ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/physiology
    Keywords covid19
    Language English
    Publishing date 2020-10-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-020-00441-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6029: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 103: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply.

    Horn, Leora / Liu, Stephen V

    The New England journal of medicine

    2019  Volume 380, Issue 9, Page(s) 889–890

    MeSH term(s) Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Humans ; Lung Neoplasms ; Small Cell Lung Carcinoma
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; atezolizumab (52CMI0WC3Y)
    Language English
    Publishing date 2019-02-27
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1900123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: How I Treat Non-Small Cell Lung Cancer Refractory to Immunotherapy.

    Wong, Selina K / Horn, Leora

    Cancer journal (Sudbury, Mass.)

    2020  Volume 26, Issue 6, Page(s) 496–501

    Abstract: Lung cancer is a leading cause of cancer-related mortality despite continued advances in diagnostic and therapeutic strategies. Although the development of immune checkpoint inhibitors has revolutionized the treatment landscape for advanced non-small ... ...

    Abstract Lung cancer is a leading cause of cancer-related mortality despite continued advances in diagnostic and therapeutic strategies. Although the development of immune checkpoint inhibitors has revolutionized the treatment landscape for advanced non-small cell lung cancer, many patients either have primary resistance to these agents or eventually develop secondary resistance necessitating a change to an alternate therapy. Understanding novel patterns of response to immunotherapy is crucial in determining appropriate selection and sequencing of treatment. Chemotherapy remains the standard of care in immunotherapy-refractory disease, but multiple trials are ongoing to explore the role of combination radioimmunotherapy and rechallenging with immunotherapy either alone or in combination with other antineoplastic agents.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Immunotherapy ; Lung Neoplasms/drug therapy
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2020-12-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 163: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Targeted/emerging therapies for metastatic non-small cell lung cancer.

    Horn, Leora

    Journal of the National Comprehensive Cancer Network : JNCCN

    2015  Volume 13, Issue 5 Suppl, Page(s) 676–678

    Abstract: ... 20th Annual Conference, Dr. Leora Horn focused attention on both approved and emerging therapies ...

    Abstract At one time, histology alone guided treatment decisions in non-small cell lung cancer (NSCLC), but now molecular diagnostics help to categorize patients with lung cancer by driver mutations. This additional information arms oncologists with the keys to selecting the right targeted agent with the best chance of success for different subgroups of patients with NSCLC. During her presentation at the NCCN 20th Annual Conference, Dr. Leora Horn focused attention on both approved and emerging therapies in metastatic disease that target an assortment of molecular subsets, such as EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF mutations.
    MeSH term(s) Anaplastic Lymphoma Kinase ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Molecular Targeted Therapy/methods ; Mutation/drug effects ; Mutation/genetics ; Practice Guidelines as Topic ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Receptor Protein-Tyrosine Kinases/genetics
    Chemical Substances Antineoplastic Agents ; Proto-Oncogene Proteins ; ALK protein, human (EC 2.7.10.1) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; ROS1 protein, human (EC 2.7.10.1) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2015-05-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2015.0201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Current Landscape of Personalized Therapy.

    Horn, Leora / Cass, Amanda S

    Thoracic surgery clinics

    2020  Volume 30, Issue 2, Page(s) 121–125

    Abstract: Almost a half of patients diagnosed with nonesmall-cell lung cancer (NSCLC) present with incurable disease, and a significant number of patients who are treated with curative intent for early-stage disease will eventually recur. Systemic therapy is ... ...

    Abstract Almost a half of patients diagnosed with nonesmall-cell lung cancer (NSCLC) present with incurable disease, and a significant number of patients who are treated with curative intent for early-stage disease will eventually recur. Systemic therapy is selected based on tumor histology, squamous versus nonsquamous NSCLC, molecular testing, and PD-L1 score. Depending on PD-L1 score, patients are eligible for immunotherapy alone or in combination with chemotherapy in the first-line setting. Oncogenic driver mutations can be detected in approximately 50% of patients with nonsquamous NSCLC of which several can be targeted therapeutically with small molecular inhibitors. Continued research is needed for more specific agents with less toxicity and better central nervous system penetration, and agents to treat patients who develop resistance against targeted treatments and immunotherapy.
    MeSH term(s) B7-H1 Antigen/immunology ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/therapy ; Humans ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Pharmacogenetics ; Precision Medicine/methods ; Precision Medicine/trends
    Chemical Substances B7-H1 Antigen ; CD274 protein, human
    Language English
    Publishing date 2020-04-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2149218-9
    ISSN 1558-5069 ; 1547-4127
    ISSN (online) 1558-5069
    ISSN 1547-4127
    DOI 10.1016/j.thorsurg.2020.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1358: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Advances in the treatment of non-small cell lung cancer.

    Horn, Leora

    Journal of the National Comprehensive Cancer Network : JNCCN

    2014  Volume 12, Issue 5 Suppl, Page(s) 764–767

    Abstract: ... During her presentation at the NCCN 19th Annual Conference, Dr. Leora Horn highlighted 3 specific areas ...

    Abstract Clinical trial data continue to emerge on treatments in advanced non-small cell lung cancer (NSCLC), supporting the strategy that histology and molecular driver mutations should guide treatment selection. During her presentation at the NCCN 19th Annual Conference, Dr. Leora Horn highlighted 3 specific areas in which the 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC focus attention: updates on the assortment of chemotherapy options, targeted therapies and how acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors appears to have become the catalyst of the development of newer-generations of agents, and the revisited role of newer immunotherapeutic options.
    MeSH term(s) Carcinoma, Non-Small-Cell Lung/therapy ; Humans ; Lung Neoplasms/therapy
    Language English
    Publishing date 2014-05-17
    Publishing country United States
    Document type Editorial ; Review
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2014.0185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Immune Checkpoint Inhibition in Lung Cancer: The Good, the Bad, and the Ugly.

    Beckermann, Kathryn / Horn, Leora

    Oncology (Williston Park, N.Y.)

    2016  Volume 30, Issue 8, Page(s) 722–723

    Language English
    Publishing date 2016
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 372: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.

    Singhi, Eric K / Horn, Leora

    Future oncology (London, England)

    2018  Volume 14, Issue 18, Page(s) 1781–1787

    Abstract: Despite significant advancements in the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) since the advent of crizotinib, the development of acquired resistance and poor CNS efficacy have necessitated the search ... ...

    Abstract Despite significant advancements in the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) since the advent of crizotinib, the development of acquired resistance and poor CNS efficacy have necessitated the search for novel and more robust therapies. Ensartinib (X-396) is a novel second-generation ALK-tyrosine kinase inhibitor (TKI) that holds much clinical promise. Preclinical data have demonstrated increased potency of the drug as compared with crizotinib and other second-generation ALK-TKI therapies such as alectinib and ceritinib. This review highlights the first- and second-generation ALK inhibitors approved for the treatment of ALK-positive NSCLC and discusses the clinical trial protocol for the eXalt3 trial (NCT02767804) comparing the efficacy and safety of ensartinib to crizotinib in patients diagnosed with ALK-positive NSCLC who are naive to prior ALK-TKI treatment.
    MeSH term(s) Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Anaplastic Lymphoma Kinase/genetics ; Antineoplastic Agents/therapeutic use ; Carbazoles/pharmacology ; Carbazoles/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Clinical Trials, Phase III as Topic ; Crizotinib/pharmacology ; Crizotinib/therapeutic use ; Drug Resistance, Neoplasm ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Oncogene Proteins, Fusion/genetics ; Piperazines/therapeutic use ; Piperidines/pharmacology ; Piperidines/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyridazines/therapeutic use ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Randomized Controlled Trials as Topic ; Research Design ; Sulfones/pharmacology ; Sulfones/therapeutic use ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; CH5424802 ; Carbazoles ; EML4-ALK fusion protein, human ; Oncogene Proteins, Fusion ; Piperazines ; Piperidines ; Protein Kinase Inhibitors ; Pyridazines ; Pyrimidines ; Sulfones ; Crizotinib (53AH36668S) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1) ; ceritinib (K418KG2GET) ; ensartinib (SMA5ZS5B22)
    Language English
    Publishing date 2018-03-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2184533-5
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2017-0619
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top